2019
Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
Yilmaz A, Fuchs D, Price RW, Spudich S, Blennow K, Zetterberg H, Gisslén M. Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. Current HIV/AIDS Reports 2019, 16: 76-81. PMID: 30649659, PMCID: PMC6420419, DOI: 10.1007/s11904-019-00420-1.Peer-Reviewed Original ResearchConceptsCSF neurograninCerebrospinal fluidProinflammatory cytokines IL-1βGroup of HIVLewy body dementiaCerebrospinal fluid concentrationsCytokines IL-1βLevels of neurograninNeuro-HIVNeurogranin concentrationsHIV neuropathogenesisSynaptic injuryHIV infectionIL-1βNeurocognitive disordersFrontal cortexParkinson's diseaseUninfected controlsReviewThe aimAlzheimer's diseaseNeurological disordersFrontotemporal dementiaNeurodegenerative disordersFluid concentrationsHIV
2009
Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection. PLOS ONE 2009, 4: e6877. PMID: 19721718, PMCID: PMC2731205, DOI: 10.1371/journal.pone.0006877.Peer-Reviewed Original ResearchConceptsHIV-1 infectionRaltegravir concentrationsCerebrospinal fluidTreatment-experienced HIV-1-infected patientsSystemic HIV-1 infectionHIV-1-infected patientsHIV-1-infected individualsIntegrase inhibitorsCentral nervous system penetrationAntiretroviral treatment regimensDrug entryPlasma albumin ratioCerebrospinal fluid concentrationsBlood-CSF barrierCSF albumin concentrationPlasma raltegravir concentrationsTreatment regimensAlbumin ratioDrug classesCSF specimensHIV-1CSF samplesAlbumin concentrationFluid concentrationsLiquid chromatography-tandem mass spectrometry